Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

This study aims to find the proposed dose of Rifapentine (RPT) taken once daily with Isoniazid (INH) for 28 days to prevent tuberculosis (TB). The study will take place at multiple locations and children under 13 years old will be divided into two groups: one group will include children without HIV, and the other group will include children with HIV who are on antiretroviral treatment. Up to 144 children will participate, and participants in each group will be followed for 24 weeks.

开始日期2026-05-15

申办/合作机构

National Institute of Allergy & Infectious Diseases

[+1]

NCT07069582

/ Not yet recruiting临床1期IIT

Plasma and Breastmilk Exposures to Antituberculosis Drugs in Breastfeeding Women: an Open-label, Randomized, Six-arm, Single-dose, Pharmacokinetic Study

This study is a sub-study of the SSTARLET trial (NCT06498414). The overall aim is to assess the pharmacokinetic profiles after taking a single dose of rifampicin, isoniazid, levofloxacin, rifapentine, and bedaquiline in breastfeeding women and the excretion of these drugs in breast milk, with the hope of including breastfeeding women in future clinical trials of TPT, including expanding the inclusion criteria of the SSTARLET trial. In this study, healthy breastfeeding women who fulfill the eligibility criteria will be enrolled from several primary health care centers in Bandung, which will be referred to the TB Research Clinic of the Universitas Padjadjaran, Bandung, Indonesia. Ten participants will be randomized to each of the following six study arms:
* Arm A: Single-dose rifampicin at 10 mg/kg body weight (RIF10).
* Arm B: Single-dose rifampicin at 20 mg/kg body weight (RIF20).
* Arm C: Single-dose isoniazid at 5 mg/kg body weight (INH5).
* Arm D: Single-dose levofloxacin at 10-15 mg/kg body weight (LFX10-15).
* Arm E: Single-dose rifapentine at 10 mg/kg body weight (RPT10).
* Arm F: Single-dose bedaquiline at 400 mg (BDQ400).

开始日期2026-04-01

申办/合作机构

Universitas Padjadjaran

ChiCTR2600116528

/ Not yet recruitingN/AIIT

Research on key technologies and strategies for preventive intervention of key populations with latent tuberculosis infection

开始日期2025-12-01

申办/合作机构-

100 项与异烟肼相关的临床结果

登录后查看更多信息

100 项与异烟肼相关的转化医学

登录后查看更多信息

100 项与异烟肼相关的专利（医药）

登录后查看更多信息

25,506

项与异烟肼相关的文献（医药）

2026-06-01·TALANTA

Integrated electrochemical platform modified with a carbon black–cerium oxide nanocomposite for the simultaneous sensing of rifampicin and isoniazid in biological and environmental samples

Article

作者: Cincotto, Fernando Henrique ; Nossol, Edson ; da Silva, Michele Verena Conceição Oliveira ; de Oliveira, Gustavo Zanon de Moraes Goes ; de Faria, Lucas Vinicius ; Santelli, Ricardo Erthal ; Lopes, Claudio Sabbatini Capella ; Ribeiro, Emerson Schwingel ; Silva, Francisco Walison Lima

Tuberculosis is a major infectious disease with high global mortality, and its first-line drugs, rifampicin (RIF) and isoniazid (INZ), are associated with serious adverse effects and public health risks when improperly administered, due to toxicity, environmental residues, and the potential induction of mycobacterial resistance. Low-cost, rapid analytical methods with simple instrumentation, particularly electrochemical approaches using screen-printed carbon electrodes (SPCE), are highly desirable for detecting these drugs. In this work, a novel electrochemical method for the simultaneous quantification of RIF and INZ was developed employing linear sweep voltammetry (LSV) as the analytical technique. As an electrochemical platform, a miniaturized and portable carbon-integrated substrate system was modified via drop-casting using a nanocomposite based on carbon black (CB) with cerium oxide (CeO₂), which was comprehensively characterized using structural, morphological, and electrochemical analyses. Importantly, this CB/CeO₂ material offered a drastic synergic effect for improving the electrochemical response of both antibiotics. The voltammetric strategy provided wide linear ranges for INZ (3.66 to 343.0 μmol L^-1) and RIF (0.611 to 57.3 μmol L^-1) with limits of detection of 0.638 μmol L^-1 and 0.0390 μmol L^-1, respectively. In addition, the sensor exhibited excellent fabrication reproducibility with RSD <4.76 %, as well as high selectivity for the analyte, making SPCE/CB/CeO₂ applicable to tap water, human urine, and synthetic human serum, with satisfactory recoveries ranging from 96.9 to 106 % demonstrating its potential for monitoring aquatic and biological matrices.

2026-06-01·BIOORGANIC CHEMISTRY

Isoniazid-derived vanillin and Salicylaldehyde Hydrazones: Promising Antimycobacterials with KatG-dependent activation

Article

作者: Kremer, Laurent ; Henry, Natacha ; Gupta, Nikita ; Roquet-Baneres, Francoise ; Anand, Amit ; Roussel, Pascal ; Kumar, Vipan

A series of hydrazones derived from vanillin and salicylaldehyde, incorporating isoniazid (INH) and its analogues (nicotinic hydrazide and pyrazine-2-carbohydrazide), were designed, synthesized, and evaluated for anti-mycobacterial activity. The INH-bearing derivatives demonstrated significant activity against Mycobacterium tuberculosis (Mtb), with MIC values of 0.078-0.625 μg/ml. Salicylaldehyde-based hydrazones exhibited the highest potency (MIC = 0.078 μg/ml), whereas vanillin analogs showed marginally reduced activity, potentially due to linker length effects. All compounds were non-toxic to THP-1 macrophages at concentrations <10 μg/ml, suggesting a favourable safety profile. UV-vis studies showed that the salicylaldehyde-based hydrazone 5d is stable under mildly acidic conditions, suggesting that pH-triggered release of INH is unlikely inside Mtb infected cells. Additionally, their lack of activity against INH-resistant Mtb KatG mutants (MIC >10 μg/ml) implies a KatG-dependent activation mechanism, analogous to INH. These findings highlight the promise of Schiff base dimerization in developing safe and potent anti-tubercular agents, warranting further chemical optimization.

2026-04-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

The first reported case of combined occlusion of branch retinal artery and vein secondary to disseminated mycobacterium kansasii infection

Article

作者: Lin, Binwu ; Qin, Lin ; Luo, Baohua ; Pang, Long ; Luo, Yanhua

BACKGROUND:

Combined occlusion of branch retinal artery and vein in young patient is rare and indicates a high risk of underlying systemic disease. Retinal arteriovenous occlusion secondary to Mycobacterium kansasii (M. kansasii) infection has never been reported.

CASE PRESENTATION:

A 37-year-old woman, previously healthy and with nothing remarkable in her family history, presented to the ophthalmology clinic due to a 1-week history of blurred vision and inferior shadow of her right eye. She had been experiencing coughing with phlegm for one month prior to the eye symptoms. Upon examination, it was found that she had a simultaneous occlusion of branch retinal artery and branch retinal vein. Laboratory investigations revealed significant inflammation and hypercoagulability. Computed tomography revealed abnormally intense metabolic activity affecting the lungs, mediastinum, spleen, nasopharynx, neck, and bones. After three months, M. kansasii was identified through DNA sequencing of pathological tissue sections, leading to a diagnosis of disseminated M. kansasii infection. Although the medications (Rifampin, Isoniazid, Ethambutol, Clarithromycin) were administered according to standardized diagnostic and therapeutic guidelines as soon as the diagnosis was made, the patient was unable to complete the full course of medications due to her inability to tolerate the side effects of the medications. The patient's condition eventually worsened and resulted in death.

CONCLUSIONS:

This is the first case of M. kansasii-associated hypercoagulability resulting in retinal arteriovenous occlusion. Disseminated Mycobacterium kansasii (DMK) infection is a rare but serious disease that can affect multiple organ systems. Rare retinal arteriovenous occlusion in young patients is often indicative of systemic disease and requires thorough evaluation to avoid misdiagnosis.

140

项与异烟肼相关的新闻（医药）

2026-02-26

·北京医学感染与传染研究

临床传染病学 82卷1-2期、增刊1期（2026年2月26日更新）

Clinical Infectious Diseases Volume 82 Issue 1 临床传染病学 82卷1期 https://academic.oup.com/cid/issue/ ID Art Through the Ages（穿越时代的传染病学技艺） 1 Peasants' Revolt, 1381 1381年农民起义 Mary Grizzard and Michael Grizzard Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page i, https://doi.org/10.1093/cid/ciaf692 In the Literature（文献概览） 2 In the Literature 文献概览 Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages ii–iii, https://doi.org/10.1093/cid/ciaf631 State-of-the-Art Review（最新技术综述） 3 State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis 最新技术综述：急性和慢性细菌性前列腺炎的诊断与治疗 Prathit A Kulkarni and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 1–13, https://doi.org/10.1093/cid/ciaf483 Clinical Dilemmas in Infectious Diseases（传染病临床难题） 4 “Insisting on Treatment” “坚持治疗” Kevin Andrew Smith and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 14–18, https://doi.org/10.1093/cid/ciaf282 Voices of ID（传染病之声） 5 Martin Arrowsmith and Me 马丁·阿罗史密斯与我 Janet R Gilsdorf Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 19–20, https://doi.org/10.1093/cid/ciaf277 Invited Commentary（特邀述评） 6 The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions 2025年美国疾病控制与预防中心非职业性艾滋病毒暴露后预防指南：更新方案及遗留问题 Lao-Tzu Allan-Blitz and Kenneth H Mayer Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 21–24, https://doi.org/10.1093/cid/ciaf567 Antimicrobial Resistance and Stewardship（抗菌药物耐药性与管控） 7 Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings 资源有限环境下，基于培养的分子检测法对抗菌药物耐药性的影响和成本建模 Joshua M Chevalier and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 25–32, https://doi.org/10.1093/cid/ciaf236 8 The Xpert MTB/RIF Cycle Threshold Value Predicts Mycobacterium tuberculosis Transmission to Close Contacts in a Brazilian Prospective Multicenter Cohort 巴西一项前瞻性多中心队列研究中Xpert MTB/RIF循环阈值可预测结核分枝杆菌在密切接触者中的传播 Leandro S Garcia and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 33–41, https://doi.org/10.1093/cid/ciad794 9 Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission 超越诊断：Xpert循环阈值作为结核病传播的预测指标 Lauren Linde and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 42–43, https://doi.org/10.1093/cid/ciad791 10 First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa 铜绿假单胞菌在头孢吡肟-齐德巴坦治疗中出现耐药性的首例报告 Ava J Dorazio and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 44–48, https://doi.org/10.1093/cid/ciaf638 Clinical Practice and Policy（临床实践与政策） 11 Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis 痰液和舌拭子分子检测用于未筛选家庭接触者结核病居家诊断的成本及成本效益分析 Charl Bezuidenhout and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 49–57, https://doi.org/10.1093/cid/ciaf389 12 You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists 我是你的朋友：传染病临床医生向传染病药剂师咨询的即兴问题 Matthew R Davis and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 58–61, https://doi.org/10.1093/cid/ciaf250 13 Home Testing for Contagious Illness: Historical Context and Modern Caveats 传染性疾病居家检测：历史背景与现代注意事项 Abigail Zuger Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 62–66, https://doi.org/10.1093/cid/ciaf623 Fungal Infections（真菌感染） 14 Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial 评估低剂量氟胞嘧啶治疗隐球菌性脑膜炎的临床试验 Morris K Rutakingirwa and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 67–74, https://doi.org/10.1093/cid/ciaf432 15 Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals 美国各医院中接受棘白菌素经验性治疗的念珠菌血症成年住院患者中，念珠菌血症持续时间与临床和医疗资源利用结局之间的关联 Thomas P Lodise and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 75–85, https://doi.org/10.1093/cid/ciaf472 16 Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data 美国隐球菌病导致的死亡率分析：基于死亡证明数据 Thomas J Walsh and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 86–92, https://doi.org/10.1093/cid/ciaf653 HIV/AIDs（人类免疫缺陷病毒/艾滋病） 17 Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data 晚期艾滋病患者危重症结局：30年的双国数据 Bryan Tan and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 93–99, https://doi.org/10.1093/cid/ciaf362 18 Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357 长效卡博特韦和VRC07-523LS用于HIV-1感染成人病毒抑制的2期试验：ACTG A5357 Babafemi O Taiwo and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 100–108, https://doi.org/10.1093/cid/ciaf375 19 Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study 全国HIV-1感染者队列中长效卡博特韦和利匹韦林的治疗药物监测：ANRS-MIE CARLAPOP研究的首批结果 Nadège Néant and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 109–118, https://doi.org/10.1093/cid/ciaf385 20 Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility? 长效卡博特韦和利匹韦林的治疗药物监测是否具有临床实用性？ Catia Marzolini Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 119–121, https://doi.org/10.1093/cid/ciaf386 21 Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study 多替拉韦/拉米夫定双药治疗在CD4计数<200/mm³的初治患者中的疗效和安全性：DOLCE研究48周结果 Maria Ines Figueroa and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/cid/ciaf415 22 DOLCE: Sweet Success for Dolutegravir/Lamivudine? DOLCE研究：多替拉韦/拉米夫定双药治疗是否取得完美成功？ Laura J Waters Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 132–133, https://doi.org/10.1093/cid/ciaf416 Infection Control and Hospital Epidemiology（感染控制与医院流行病学） 23 Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact 实时基因组监测用于加强医疗保健机构疫情检测与控制：临床与经济影响 Alexander J Sundermann and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 134–141, https://doi.org/10.1093/cid/ciaf216 24 Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions 两家医院患者对耐甲氧西林金黄色葡萄球菌不同接触预防政策的态度：患者支持接触预防措施 Nicholas F Angelino and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 142–144, https://doi.org/10.1093/cid/ciaf330 Photo Quiz（影像问答） 25 The Clue That Wriggled into View 蜿蜒入目的线索 Nitin Gupta and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 145–147, https://doi.org/10.1093/cid/ciaf427 Infection Control and Hospital Epidemiology（感染控制与医院流行病学） 26 Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection 比较生成式人工智能与专家在导管相关尿路感染检测中的应用 Shatha Alshanqeeti and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 148–150, https://doi.org/10.1093/cid/ciaf486 Sexually Transmitted Infections（性传播感染） 27 Viability of Chlamydia trachomatis in Different Anatomical Sites—a Systematic Review and Meta-analysis 不同解剖部位沙眼衣原体的存活能力——系统综述和荟萃分析 Arthur Wong and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 151–158, https://doi.org/10.1093/cid/ciae401 Photo Quiz（影像问答） 28 A 46-Year-Old With Persistent Altered Mental Status and Respiratory Failure 一例46岁患者持续出现意识状态改变伴呼吸衰竭 Ann F Yang and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 159–161, https://doi.org/10.1093/cid/ciaf439 Sexually Transmitted Infections（性传播感染） 29 Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort HIV感染者中的猴痘：多站点队列中诊断、预后和疫苗有效性的预测因素 Michalina Montaño and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 162–172, https://doi.org/10.1093/cid/ciae464 30 Development and Evaluation of a Novel Algorithm to Identify Doxycycline Postexposure Prophylaxis Users at a Large Healthcare System in the Bronx, New York 开发和评估一种新型算法，用于识别纽约布朗克斯区一家大型医疗系统中多西环素暴露后预防用药者 Caroline E Mullis and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 173–176, https://doi.org/10.1093/cid/ciaf109 31 Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections 为预防细菌性性传播感染提供基于证据的多西环素暴露后预防用药 Julia C Dombrowski and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 177–184, https://doi.org/10.1093/cid/ciae527 Bacterial Infections（细菌性感染） 32 Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil 巴西结核病患者的长期死亡率趋势：一项针对巴西结核病诊断患者的回顾性队列研究 Sun Kim and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e1–e8, https://doi.org/10.1093/cid/ciaf206 33 Clinical and Microbiological Characteristics of Meningococcal Eye Infections: Retrospective National Surveillance in England, 2010–2022 脑膜炎球菌眼部感染的临床和微生物学特征：2010 - 2022年英格兰全国回顾性监测 Stephen A Clark and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e9–e16, https://doi.org/10.1093/cid/ciaf274 34 Does Piperacillin-Tazobactam Increase Mortality Risk Compared With Cefepime? Collider Bias and the Importance of Assumptions in Instrumental Variable Analyses 与头孢吡肟相比，哌拉西林-他唑巴坦是否会增加死亡率风险？工具变量分析中的混杂偏倚和假设的重要性 Fergus Hamilton and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e17–e23, https://doi.org/10.1093/cid/ciaf317 COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型） 35 Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study 奥贝德西韦在高危非住院COVID-19患者（BIRCH研究）中的疗效和安全性：一项3期、随机、双盲、安慰剂对照研究 Anca Streinu-Cercel and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e24–e32, https://doi.org/10.1093/cid/ciaf406 36 Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity COVID-19症状复发且SARS-CoV-2检测呈阳性后使用奈玛特韦/利托那韦重新治疗 Wuyan Zhang and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e33–e40, https://doi.org/10.1093/cid/ciaf548 Emerging Infections(新兴感染) 37 “I Didn’t Know Him Before the Pandemic… Now He's on My Speed Dial”: Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies “疫情前我并不认识他……现在他已是我的快速拨号对象”：加强传染病医生与州和地方公共卫生部门在未来突发公共卫生事件中的合作 Diana Valencia and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e41–e46, https://doi.org/10.1093/cid/ciaf179 38 Identification of and Response to Influenza A(H5) in Off-the-Shelf Raw Milk—Santa Clara County, California, November–December 2024 2024年11 - 12月加利福尼亚州圣克拉拉县在现成生牛奶中检出甲型流感（H5）病毒及应对措施 Alessandra Løchen and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e47–e48, https://doi.org/10.1093/cid/ciaf420 39 The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness 小分子抗病毒药物在流行病和大流行病防范中的不可或缺价值 Ruxandra Draghia-Akli and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e49–e55, https://doi.org/10.1093/cid/ciaf476 HIV/AIDs（人类免疫缺陷病毒/艾滋病） 40 Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative 在紧急护理和急诊科进行淋病和衣原体检测时增加HIV检测：一项大型医疗系统倡议 Allan M Seibert and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e56–e67, https://doi.org/10.1093/cid/ciaf434 41 Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada 美国和加拿大“全员治疗”时代男性HIV感染者卡波西肉瘤的临床预测因素和发病率 Sally B Coburn and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e68–e77, https://doi.org/10.1093/cid/ciaf446 42 Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes 美国接受过治疗的围产期感染HIV的年轻成人使用整合酶链转移抑制剂的免疫学、病毒学和人体测量学结果 Kunjal Patel and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e78–e88, https://doi.org/10.1093/cid/ciaf538 43 Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings Win比值与REPRIEVE研究的主要发现一致并增强了其解释性 Emma Davies Smith and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e89–e92, https://doi.org/10.1093/cid/ciaf477 44 The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States 临床应用案例对于指导即时检测技术开发的重要性：以美国HIV核酸检测为例 Yukari C Manabe and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e93–e99, https://doi.org/10.1093/cid/ciaf510 Mycobacterial Infections（分枝杆菌感染） 45 Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts 结核密切接触者中体重指数与新发结核病的关系 María B Arriaga and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e100–e109, https://doi.org/10.1093/cid/ciaf475 46 The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study 青年在家庭内结核病传播中的作用：一项家庭接触队列研究 Meredith B Brooks and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e110–e118, https://doi.org/10.1093/cid/ciaf490 47 Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa 南非以靶向下一代测序作为结核病耐药检测标准护理方案的替代方案的成本效益分析 Alexandra de Nooy and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e119–e125, https://doi.org/10.1093/cid/ciaf495 48 Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification Xpert MTB/RIF循环阈值作为结核病（TB）疾病严重程度的标志物：对结核病治疗分层的启示 Daniel J Grint and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e126–e134, https://doi.org/10.1093/cid/ciaf527 49 The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials β-内酰胺类抗生素在治疗脓肿分枝杆菌中的作用：从实验室见解到临床应用及开展临床试验的必要性 Khalid M Dousa and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e135–e145, https://doi.org/10.1093/cid/ciaf547 Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病） 50 Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine 一种研究性孕产妇呼吸道合胞病毒融合前F蛋白疫苗的疗效、免疫原性和安全性 Peyman Banooni and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e146–e155, https://doi.org/10.1093/cid/ciaf033 51 Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics HIV感染者在孕期和产后接受异烟肼预防性治疗时的肝毒性：抗逆转录病毒治疗方案和药物基因组学的作用 Grace Montepiedra and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e156–e164, https://doi.org/10.1093/cid/ciaf198 52 Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood 青蒿素、甲氟喹和哌喹的胎盘转运：母亲、新生儿和脐带血中浓度的比较 Makoto Saito and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e165–e173, https://doi.org/10.1093/cid/ciaf552 53 Why Did the Antimalarial Drug Cross the Placenta? 抗疟药为何要穿过胎盘？ Stephen J Rogerson and Holger W Unger Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e174–e175, https://doi.org/10.1093/cid/ciaf553 Viral Infections（病毒性传染病） 54 Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection HIV和慢性乙型肝炎病毒（HBV）共感染患者开始使用HBV活性抗逆转录病毒治疗后乙型肝炎表面抗原消失的动力学和预测因素 Jennifer Audsley and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e176–e184, https://doi.org/10.1093/cid/ciaf281 55 Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections 患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病 Lauren A Powers and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e185–e190, https://doi.org/10.1093/cid/ciaf285 Correspondence（读者来信） 56 Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality 揭示抗菌药物耐药性菌血症中的潜在风险模式：深入探究病原体特异性死亡率 Yuan-Ti Lee and Shiuan-Chih Chen Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e191, https://doi.org/10.1093/cid/ciaf493 57 Resistance to Antibiotics With High Empiric Treatment Relevance Explains Attributable Mortality Across 110 Pathogen-antibiotic Combinations 对经验性治疗具有高度相关性的抗生素耐药性可解释110种病原体 - 抗生素组合的归因死亡率 Kevin A Brown and Nick Daneman Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e191–e192, https://doi.org/10.1093/cid/ciaf494 58 Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need 文化冲突：双病原体心内膜炎以及我们所需的宏基因组下一代测序研究 Carl Boodman and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e193–e195, https://doi.org/10.1093/cid/ciaf518 59 Metagenomic Next-Generation Sequencing and Cardiovascular Infections: Promise and Pitfalls of Polymicrobial Detection 宏基因组下一代测序与心血管感染：多微生物检测的前景与陷阱 Sarwat Khalil and M Rizwan Sohail Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e196, https://doi.org/10.1093/cid/ciaf519 60 It Is Time to Go Beyond the Association Between Colistin and Meropenem for Invasive Carbapenem-Resistant Acinetobacter baumannii Infections 是时候超越多粘菌素和美罗培南联合治疗侵袭性碳青霉烯耐药鲍曼不动杆菌感染了 Alberto Enrico Maraolo and Giancarlo Ceccarelli Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e197–e198, https://doi.org/10.1093/cid/ciaf533 61 Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant Acinetobacter baumannii (CRAB) 实际上，对于某些感染碳青霉烯耐药鲍曼不动杆菌（CRAB）的患者，或许是时候重新使用多粘菌素和美罗培南了 Jason M Pogue and Keith S Kaye Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e198–e199, https://doi.org/10.1093/cid/ciaf534 62 COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias? COVID-19和细菌性肺炎：保护作用还是诊断偏差？ Duygu Aydın and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e200, https://doi.org/10.1093/cid/ciaf539 63 Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections: A Follow Up 患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病：后续研究 John C Hu and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e200–e201, https://doi.org/10.1093/cid/ciaf540 64 Long-Acting Cabotegravir/Rilpivirine in Viremic People With HIV: Bumpy Road to Perfection 长效卡博特韦/利匹韦林用于病毒载量阳性的HIV感染者：通往完美的坎坷之路 Beatrice Barda and Marco Bongiovanni Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e201–e202, https://doi.org/10.1093/cid/ciaf482 65 Beyond the Sequence: Operationalizing Whole-Genome Sequencing for Real-time Infection Control in Low- and Middle-Income-Country Healthcare Settings Healthcare Settings 超越序列：在中低收入国家医疗环境中实际应用全基因组测序进行实时感染控制 Schawanya Kaewpitoon Rattanapitoon and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e202–e203, https://doi.org/10.1093/cid/ciaf535 66 Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases 重新评估耐多药结核病的依从性轨迹：康复优势和隐藏偏差 Shiuan-Chih Chen and Chun-Chieh Chen Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e203–e204, https://doi.org/10.1093/cid/ciaf536 67 Metagenomic Sequencing of Blood Culture Broth for Diagnosing Fastidious Endocarditis 血培养肉汤宏基因组测序用于诊断苛养性心内膜炎 Po-Hsiu Huang and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e204–e205, https://doi.org/10.1093/cid/ciaf554 Corrections（更正） 68 Correction to: Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections 《患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病》更正 Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e206, https://doi.org/10.1093/cid/ciaf572 69 Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa 《南非高HIV流行率、项目化环境中口服短程利福平耐药结核病治疗方案的治疗结果》更正 Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e207, https://doi.org/10.1093/cid/ciaf711 Clinical Infectious Diseases Volume 82 Issue Supplement_1 临床传染病学 82卷增刊1期 https://academic.oup.com/cid/issue/82/Supplement_1 SUPPLEMENT（增刊） Laboratory and Point-of-care Testing to Detect Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Available Evidence 实验室及即时检测技术用于检测沙眼衣原体和淋病奈瑟菌：现有证据综述 SUPPLEMENT ARTICLES（增刊论著） 1 Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae 美国疾病控制与预防中心沙眼衣原体和淋病奈瑟菌检测指南制定证据综述 Amanda C Smith and Ellen N Kersh Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S1–S5, https://doi.org/10.1093/cid/ciaf665 2 Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods 沙眼衣原体培养、活性检测及测序方法的叙述性综述 Alana K Sterkel and others Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S6–S12, https://doi.org/10.1093/cid/ciaf697 3 Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods 淋病奈瑟菌培养与鉴定：当前实验室方法叙述性综述 Olusegun O Soge and others Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S13–S18, https://doi.org/10.1093/cid/ciaf698 4 Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae 实验室分子诊断技术检测沙眼衣原体和淋病奈瑟菌的性能综述 Megan Crumpler and others Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S19–S35, https://doi.org/10.1093/cid/ciaf696 5 Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae 淋病奈瑟菌抗菌药物耐药性检测方法综述 Kara K Mitchell and others Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S36–S42, https://doi.org/10.1093/cid/ciaf706 6 Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature 沙眼衣原体和淋病奈瑟菌即时检测技术文献综述 Yukari C Manabe and others Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S43–S51, https://doi.org/10.1093/cid/ciaf699 Clinical Infectious Diseases Volume 82 Issue 2 临床传染病学 82卷 2期 https://academic.oup.com/cid/issue/ ID Art Through the Ages（穿越时代的传染病技艺） 1 Interior of the Old Jersey Prison Ship in the Revolutionary War 美国革命战争中老泽西监狱船的内部景象 Mary Grizzard and Michael Grizzard Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693 In the Literature（本期精选） 2 In the Literature 本期精选 Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011 IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论） 3 2025 Content Collections from the IDSA Journals IDSA期刊2025年内容合集 Roger Bedimo and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041 State-of-the-Art Review（前沿综述） 4 State-of-the-Art Review: Chagas Disease—an Enduring Challenge 前沿综述：恰加斯病——一个持续存在的挑战 Nelson Iván Agudelo Higuita and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654 IDSA Features（美国传染病学会特色内容） 5 Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association 支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件 Julia L Marcus and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648 Voices of ID（传染病之声） 6 A “Terminal Infection” “绝症感染” Jennifer Furin Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332 Invited Commentary（特邀评论） 7 A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail 区分病毒与细菌感染的快速检测：寻找“圣杯” Lao-Tzu Allan-Blitz and Jeffrey D Klausner Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585 Bacterial Infections（细菌感染） 8 Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort 脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验 Emilie Marie Eriksen and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304 9 What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections? 抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？ Linda Bussini and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323 10 Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials 辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析 Francesc Escrihuela-Vidal and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387 HIV/AIDs（人类免疫缺陷病毒/艾滋病） 11 Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons 在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学 Thomas Drumel and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430 12 Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis 中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析 Lukun Zhang and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466 13 Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1 HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果 Marc Wirden and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422 14 Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence 在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法 Cameron T Nutt and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444 Mycobacterial Infections（结核分枝杆菌感染） 15 Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting 刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析 Bertin C Bisimwa and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451 16 Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country 生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验 Sandra Pérez-Recio and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491 17 Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial 减少家庭内结核病传播：一项试点整群随机对照试验 Cinthya Ruiz-Tagle and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526 18 (Un)masking Tuberculosis （揭开）结核病的“面具” Joseph N Burzynski and Neil W Schluger Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528 19 Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM) 评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM） Lucía CarratalàCastro and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525 Sexually Transmitted Infections（性传播感染） 20 Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections 多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响 Michael W Traeger and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488 21 Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections 填补空白：多西环素预防细菌性性传播感染的最新进展 Aniruddha Hazra and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062 22 Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022 2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现 Sarah B Wondmeneh and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015 Viral Infections（病毒性感染） 23 Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling 通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用 Sithembiso Velaphi and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098 Photo Quiz（影像问答） 24 Bursting at the Seams “撑破” Maxwell Olenski and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488 Viral Infections（病毒性感染） 25 Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021 2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查 Nayab Mehmood and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151 26 Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication 灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分 Konstantin Chumakov and Stanley A Plotkin Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215 Photo Quiz（影像问答） 27 Intracranial Lesion in a Patient With Chronic Myeloid Leukemia 慢性髓性白血病患者颅内病变 Mohammed Shakeel Sillat and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441 Viral Infections（病毒性感染） 28 Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020 在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据 Justin Z Amarin and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194 29 Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection 一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注 Astrid Wintering and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125 Clinical Trials（临床实验） 30 Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial 干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验 Michelle K Yong and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409 31 A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8 一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验 Paul T Scott and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604 32 Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial 直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验 David C Gaston and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677 33 The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship 对完美诊断检测的诱人追求：平衡创新与管理 K C Coffey and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674 Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病） 34 Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein 在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白 Rebecca Crowder and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549 HIV/AIDs（人类免疫缺陷病毒/艾滋病） 35 Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2 通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估 Steven K Grinspoon and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542 36 REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少 Matthew S Durstenfeld Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543 37 Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study) 在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究） Sergio Serrano-Villar and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565 38 Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale? 丙酚替诺福韦与体重：我们最终是否打破了平衡？ John R Koethe Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566 39 Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study 在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局 Gbolahan Ajibola and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568 40 Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023 2015-2023年美国开具HIV暴露后预防处方的患者趋势 John N Le and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581 Immunocompromised Hosts（免疫功能低下宿主） 41 Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen 根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后 Anne-Sophie Brunel and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134 42 An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant 在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响 Genovefa A Papanicolaou and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646 43 Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients 在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用 Ajit P Limaye and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632 44 The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined 来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定 Yoichiro Natori and Martina Sester Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633 45 IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes 北美出现的IL12RB1缺陷：拓展临床表型 Chen Wang and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637 Vaccines（疫苗） 46 A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017 一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究 Raquel Ron and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435 47 Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines 与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性 Omid Rezahosseini and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455 48 Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns 健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应 Audrey Godin and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484 49 Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season 老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果 Sara Y Tartof and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496 Sexually Transmitted Infections（性传播感染） 50 Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID) 生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析 Kay Htaik and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295 51 Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022 2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况 Guoyu Tao and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314 52 Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083 卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析 Meredith E Clement and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572 Viral Infections（病毒性感染） 53 Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus 对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析 Paulina Sudnik and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310 54 In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines 处于危急状况：迫切需要支持猴痘治疗和诊断管线 Carmen Perez Casas and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529 Correspondence（读者来信） 55 Caution in Interpreting INSTIs and Weight in Observational Studies 在观察性研究中解读整合酶抑制剂与体重关系时需谨慎 Esteban Martínez Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569 56 Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort 整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性 Yuan-Ti Lee and Shiuan-Chih Chen Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570 57 Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens 现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加 Xinsheng Wu and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571 58 C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur? 结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？ Patrick K Moonan and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575 59 C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care 结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物 Lillian Tugume and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576 60 The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial 胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究 Melissa J Hardy and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587 61 Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture 效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况 Emma Davies Smith and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588 62 Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis? 口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？ Jun Suzuki and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598 63 Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis 朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进 Romane Pouy and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599 64 Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use 利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用 James S Ford and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601 65 Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions 平衡人工智能创新与实用的败血症定义 Chanu Rhee and Michael Klompas Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602 66 Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies 生物疗法中结核病的精准预防：筛查策略之外的启示 Shiuan-Chih Chen and Yuan-Ti Lee Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559 67 Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps 重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训 Nathkapach K Rattanapitoon and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605

2026-02-23

·医讯护通

中国银屑病生物治疗专家共识（2019）核心总结

本共识由中华医学会皮肤性病学分会等三大协会制定，结合中国患者特点与国内外研究/临床数据，明确了银屑病生物制剂的临床应用规范，为临床合理、安全使用生物制剂提供具体指导，适用于我国已上市并临床应用的银屑病生物制剂。一、共识制定基础与涵盖制剂1. 制定依据：国内注册临床数据、国外上市前数据、国际指南/共识、真实世界研究数据及专家临床经验。2. 涵盖制剂：仅纳入我国获批上市的品种，分三类 ◦ TNF-α抑制剂：依那西普、英夫利西单抗、阿达木单抗 ◦ IL-12/23抑制剂：乌司奴单抗 ◦ IL-17A抑制剂：司库奇尤单抗研发中、国外上市国内未获批的制剂暂不纳入。二、各生物制剂核心临床应用明确各制剂的适应证（含国内获批+国外获批+超适应证）、使用方法、疗效（以PASI75/PASI90为核心指标）及不良反应，核心特点如下：1. 依那西普：结核/乙肝再激活风险低，注射部位反应为最常见不良反应，儿童（4~17岁）可用药。2. 英夫利西单抗：静脉输注，起效快、疗效高，输液反应为常见不良反应，严重不良反应含乙肝再激活、严重感染等。3. 阿达木单抗：皮下注射，疗效稳定，儿童（4~<18岁）临床研究显示疗效良好，常见感染、注射部位反应。4. 乌司奴单抗：给药间隔长（每12周），中国患者12周PASI75达82.5%，长期疗效佳，罕见严重超敏反应。5. 司库奇尤单抗：中国患者疗效突出，12周PASI75达97.7%、PASI90达80.9%，常见上呼吸道感染，慎用于炎症性肠病患者。三、生物治疗核心应用原则1. 适用人群：中重度斑块状银屑病（传统治疗无效/不耐受）、关节病型银屑病（抗风湿药无效），泛发性脓疱型/红皮病型银屑病可综合评估后超适应证使用。2. 治疗选择：斑块状银屑病可选用司库奇尤单抗、乌司奴单抗或TNF-α抑制剂；关节病型优先TNF-α抑制剂；结核/乙肝/心衰高风险者优选司库奇尤单抗、乌司奴单抗。3. 疗效评估：达标标准为皮损完全清除/PASI90，最低标准为PASI50/生活质量改善。4. 维持与停药：达标并维持6个月以上可停药/减量维持；重症/顽固/伴关节损害者建议长期维持；出现严重不良反应立即停药。5. 重启治疗：重症复发需重新诱导（依那西普除外），英夫利西单抗不推荐再次诱导，轻症复发可直接用维持方案。四、用药前筛查与治疗中监测 1. 用药前必查：血常规、肝功能、肾功能、HBV/HCV血清学、PPD/T-Spot、胸部X线/CT，育龄期女性查尿妊娠试验，拟用TNF-α抑制剂查抗核抗体，高危人群查HIV。 2. 治疗中监测：血常规/肝功能按制剂不同定期检查；HBV/HCV阳性者每3~6个月复查；TNF-α抑制剂每半年查抗核抗体、PPD/T-Spot、胸部影像，其他制剂每年查1次。五、联合治疗规范 1. 推荐联合：生物制剂+外用糖皮质激素/维生素D3衍生物（提高疗效）；疗效不佳者可联合甲氨蝶呤/阿维A。 2. 谨慎/不推荐联合：不推荐常规联合紫外线光疗（潜在皮肤肿瘤风险）；不推荐与环孢素联用；不推荐不同生物制剂常规联用（严重感染/肿瘤风险）。六、疗效衰减的应对 1. 定义：原发性失败为首次用药未达临床标准；继发性失败（疗效衰减）为初期有效后疗效下降，原因含抗药物抗体（ADA）、剂量不足等。 2. 对策：联用甲氨蝶呤降低ADA；增加剂量/缩短用药间隔；换用其他生物制剂；转换传统治疗。 3. 洗脱期：换生物制剂建议停药3~4个半衰期，病情允许时执行；转传统治疗无需洗脱期。七、特殊人群应用注意事项 1. 妊娠期/哺乳期 • 生物制剂为妊娠期三线治疗，FDA评级均为B，无明确生殖毒性/致畸报告。 • 备孕期需按制剂停药：依那西普3周、阿达木单抗20周、英夫利西单抗24周、司库奇尤单抗20周、乌司奴单抗15周。 • 哺乳期：英夫利西单抗/乌司奴单抗避免哺乳；司库奇尤单抗权衡利弊，治疗期间及停药后20周可考虑停止哺乳。 2. 儿童国内无获批儿童适应证，参考国外指南：依那西普（4岁+）、阿达木单抗（4岁+）、乌司奴单抗（12岁+）可使用，英夫利西单抗/司库奇尤单抗仅有个案报道。 3. 结核病患者 • 活动性结核禁用生物制剂；潜伏/非活动性结核需先予预防性抗结核治疗（推荐异烟肼+利福平联合4个月），治疗4周后再用生物制剂。 • 用药后定期复查结核相关指标，TNF-α抑制剂使用者增加随访频率。 4. HBV感染者 • 活动性HBV感染慎用，肝功能正常的非活动性感染需咨询肝病科，必要时联合抗HBV治疗。 • 用药后定期监测肝功能、HBV抗原抗体及HBV DNA，及时发现再激活。 5. 其他特殊情况 • 恶性肿瘤：根治术后5年无复发可谨慎使用，联合光疗/免疫抑制剂者严密监测皮肤癌，淋巴系统肿瘤不推荐使用。 • 疫苗接种：可接种灭活/重组疫苗（免疫效果可能受影响），活疫苗慎用，接种前后需停药2~3个半衰期；妊娠16周后用药者，婴儿出生后6个月避免活疫苗。 • 外科手术：中/高风险手术停药3~5个半衰期，低风险手术无需停药；术后伤口愈合良好、无感染可重启用药。八、共识局限性本共识为临床参考意见，非强制性，内容可能存在不全面之处；随着生物制剂研发和临床经验积累，将定期修订更新。

2026-02-19

·BioSpace

BioVersys and Partners’ Phase 2a Tuberculosis Trial Results Published in New England Journal of Medicine

Data from Phase 2a study demonstrated the first clinical proof of concept for alpibectir in combination with ethionamide (AlpE) in the treatment of patients with tuberculosis. The results, published in the prestigious New England Journal of Medicine, underscore the significant potential of AlpE to shape the future of TB treatment. BASEL, Switzerland, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today the publication of promising clinical proof of concept results in the prestigious New England Journal of Medicine from the Phase 2a clinical trial of AlpE in patients with pulmonary TB. 1 Tuberculosis is one of the leading causes of death by infectious diseases globally, and many existing treatments are becoming less effective due to growing drug resistance. Alpibectir, a small molecule acting through a novel mode of action, represents a totally new concept of overcoming resistance by potentiating the activity of an existing antibiotic, ethionamide (Eto), and was identified in a successful public-private collaboration with GSK, the Pasteur Institute of Lille and the University of Lille. The Phase 2a bEto-TB clinical trial was conducted in South Africa through a consortium of three partners, TASK, GSK and BioVersys, and was completed in April 2024. AlpE delivered a promising clinical proof of concept in a 7-day early bactericidal activity (EBA) study, conducted in patients with pulmonary tuberculosis. AlpE seeks to offer a replacement for isoniazid (INH) in the current first-line regimen or to be added as a novel bactericidal drug to future regimens including those of TB meningitis. The clinical development of AlpE has been strongly supported by several European Union grants and public private partnerships, including the EU Innovative Medicines Initiative 2 (IMI2), TRIC-TB project and UNITE4TB project, and the European & Developing Countries Clinical Trials Partnership (EDCTP2 programme), bEto-TB project. Dr. Glenn Dale, Chief Development Officer of BioVersys: “We are very pleased to see the favorable safety, tolerability and pharmacokinetics pro AlpE, and even more so for the promising signals of efficacy delivered from this Phase 2a clinical trial. These data give us real encouragement for the further Phase 2 studies in UNITE4TB, run by our partner GSK, where AlpE is being studied in combination with first line TB drugs. We are also excited as we plan to initiate a Phase 2 trial in meningeal TB later this year.” Michelle Nderu, Project Officer, EDCTP Association: “The bEto-TB trial demonstrates the power of sustained investment in global health research. The development of AlpE reflects not only scientific innovation but also the strength of collaborative partnerships. With support from EDCTP2, these results bring us a step closer to delivering shorter, safer and more effective treatment options for people living with TB.” Prof. Andreas Diacon, Founder and Chief Scientist at TASK: “At TASK we are grateful to our study participants whose collaboration allows yet another novel antibiotic to move a step forward. This study has shown that ethionamide, an established, low-cost and safe antibiotic, becomes more potent and better tolerated by the addition of alpibectir. The AlpE combination is now on its way to become part of drug combinations that treat tuberculosis patients with and without resistance to other drugs, and it appears particularly suitable for patients with tuberculosis meningitis where better treatments are direly needed.” Dr. David Barros-Aguirre, Head of Global Health Medicines R&D, GSK: “TB remains one of the world’s deadliest infectious diseases, and tackling drug resistance is one of the biggest challenges we face. That’s why innovation is essential. The Phase 2a results for AlpE mark an exciting step forward, demonstrating the potential of novel approaches to strengthen existing therapies. We are proud to collaborate with BioVersys, TASK and partners, to advance research aimed at transforming TB care for patients globally, particularly in lower-income countries where the disease remains most prevalent.” About bEto-TB This project brings a new anti-TB molecule, BVL-GSK098, to the current drug armamentarium. BVL-GSK098 greatly augments the activity of, and overcomes resistance to, the well-established second line drug Eto at a lower and well-tolerated dose. The objectives of this consortium are to determine the early bactericidal activity (EBA) of the combination of BVL-GSK098 and various doses of Eto. We will also evaluate the comparative anti-TB activity of bEto to that of standard dose INH and thus explore the potential for bEto as a replacement of INH in the current first-line regimen or to add a novel bactericidal drug to future regimens. The programme has previously received funding from the EU IMI 2 JU (TRIC-TB) and the Wellcome Trust. Project description website: X: Statements or views expressed in this release are those of the respective organizations or persons and the European & Developing Countries Clinical Trials Partnership is not responsible for any use of the information contained herein. About tuberculosis (TB) Tuberculosis (TB) remains one of the leading causes of death worldwide. It is caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb). According to the WHO Global Tuberculosis Report 2025, an estimated 10.7 million people developed TB in 2024, and approximately 1.23 million died from TB. Drug resistance continues to pose a major challenge. There were about 390,000 people who developed rifampicin-resistant TB (RR-TB) or multidrug-resistant TB (MDR-TB) in 2024. MDR-TB remains a public health crisis and a health security threat, with global treatment success rates at only 71%. The major burden of TB is concentrated within 30 high TB burden countries, accounting for 87% of the global total in 2024. Of those, the top eight countries for TB cases worldwide were, India (25%), Indonesia (10%), the Philippines (6.8%), China (6.5%), Pakistan (6.3%), Nigeria (4.8%), the Democratic Republic of the Congo (3.9%) and Bangladesh (3.6%). Globally, 8.3 million people were reported as newly diagnosed with TB in 2024, Significantly, it remains that 3.2% of new TB cases and 16% of previously treated cases are MDR/RR-TB. About EDCTP The vision of the European & Developing Countries Clinical Trials Partnership (EDCTP) is to reduce the individual, social, and economic burden of poverty-related infectious diseases in sub-Saharan Africa. EDCTP funds collaborative clinical research that accelerates the development of accessible, suitable, and affordable medical interventions (drugs, vaccines, and diagnostics) to identify, prevent or treat infectious diseases, including emerging and re-emerging diseases. EDCTP’s approach integrates research with the development of African clinical research capacity and networking. EDCTP2 is supported by the European Union under Horizon 2020, its Framework Programme for Research and Innovation. For more information, visit . About TASK TASK is a social enterprise committed to developing, testing, and progressing novel medicines, vaccines, and diagnostics in various medical therapeutic areas, most notably in anti-tuberculosis drugs, aimed at improving global health care. Since its inception in 2005, TASK has grown exponentially and diversified into six distinct independent clinical research sites; a mycobacteriology bio-safety level 3 laboratory; a phase I to II clinical trial hospital with twenty-four beds; two registered dispensing pharmacies; a data management centre; regulatory, quality control and compliance office and a clinical research training academy. Over the last 15 years TASK has completed multiple research projects, many of global significance, and contributed to progressing the scientific field of TB medicine and vaccine development, most notably with early bactericidal activity (EBA) studies and clinical trials that in part led to the registration of bedaquiline. Find us at and follow us on Twitter @taskapplied. About BioVersys BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3), and tuberculosis (alpibectir, Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland. BioVersys contact Hernan Levett , CFO, Tel. +41 61 633 22 50; Mail: hernan.levett@bioversys.com For media: media@bioversys.com Website: X: LinkedIn: The bEto-TB project (grant reference: RIA2019AMR-2657) is part of the EDCTP2 programme supported by the European Union. Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning BioVersys and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioVersys to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioVersys is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. 1 The Revival of Ethionamide by Alpibectir (BVL-GSK098), Michel Pieren et a l , 2026;

临床2期临床结果临床3期微生物疗法

100 项与异烟肼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00346	异烟肼	J04AC01	DB00951

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肺结核	日本	Alfresa Pharma Corp.	1986-02-25
结核	美国	Sandoz, Inc.	1952-09-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
下肢溃疡	临床2期	丹麦	Pharma 2100 ApS	2008-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04703075 (Pubmed \| PLoS Med)	临床4期	潜伏性结核	500	1 month of rifapentine and isoniazid	簾積糧夢築製壓觸願網(觸襯範鹹鑰獵糧範構憲) = 淵鏇鑰夢構鬱鏇壓顧範壓廠鹽淵餘壓夢壓衊憲 (鏇鏇壓構憲積構積廠糧 ) 更多	不佳	2026-02-10
				3 months of rifapentine and isoniazid	簾積糧夢築製壓觸願網(觸襯範鹹鑰獵糧範構憲) = 構廠網簾製膚顧廠選築壓廠鹽淵餘壓夢壓衊憲 (鏇鏇壓構憲積構積廠糧 ) 更多
NCT04311502 (Clo-Fast, CTgov)	临床2期	结核 \| 肺结核 \| HIV感染	104	Ethambutol+Rifapentine+Clofazimine loading dose+Isoniazid+Pyrazinamide (Arm 1: Experimental)	鑰艱遞鏇齋鏇壓製鑰積(網選襯鏇醖範製鏇蓋遞) = 餘窪網觸蓋鹽遞窪鏇衊餘範選壓齋築願鏇簾網 (選夢觸壓繭壓鏇衊醖醖, 窪顧淵積製繭觸繭齋蓋 ~ 鹹築夢繭淵鑰鑰醖願遞) 更多	-	2025-08-27
				Ethambutol+Rifampicin+Isoniazid+Pyrazinamide (Arm 2: Standard of Care)	鑰艱遞鏇齋鏇壓製鑰積(網選襯鏇醖範製鏇蓋遞) = 積鑰鑰夢簾鹹繭積鑰簾餘範選壓齋築願鏇簾網 (選夢觸壓繭壓鏇衊醖醖, 遞願鑰醖蓋網簾構餘遞 ~ 願鹽鑰構構鬱鬱壓蓋遞) 更多
NCT06041919 (CTgov)	临床2期	肺结核	20	RESP301 (1 (Active))	鹽鹹廠膚鑰醖糧選鏇衊(築遞衊廠範觸憲製鹽醖) = 鹹淵範艱鹹餘壓願網糧襯淵築窪網鏇顧觸鹹範 (網壓襯鏇鹽簾廠膚糧鏇, 遞窪選觸繭淵鹽築製衊 ~ 鏇襯襯衊醖獵網網衊廠) 更多	-	2025-07-15
				ethambutol+rifampicin+isoniazid+pyrazinamide (2 (Control))	鹽鹹廠膚鑰醖糧選鏇衊(築遞衊廠範觸憲製鹽醖) = 獵蓋醖繭製膚遞繭構衊襯淵築窪網鏇顧觸鹹範 (網壓襯鏇鹽簾廠膚糧鏇, 願觸觸繭壓顧選糧窪淵 ~ 齋夢積範鑰鏇餘築鹽鑰) 更多
NCT04703075 (CTgov)	临床4期	结核 \| 肺结核	531	Rifapentine+INH (Arm A: 1HP)	簾網鹽顧衊膚網鏇糧糧 = 鹽衊衊壓糧壓顧憲範夢範膚願餘淵鹹鑰醖鹽夢 (窪構憲獵觸壓築築築簾, 獵醖鑰選壓餘願憲觸鬱 ~ 築蓋壓網遞繭憲鹽積鏇) 更多	-	2025-06-19
				Rifapentine+INH (Arm B: 3HP)	簾網鹽顧衊膚網鏇糧糧 = 鏇壓艱憲範選糧築顧衊範膚願餘淵鹹鑰醖鹽夢 (窪構憲獵觸壓築築築簾, 獵願築膚簾鏇製糧衊醖 ~ 網艱鬱鹽鏇選蓋醖築範) 更多
NCT03474198 (TRUNCATE-TB, Pubmed \| Lancet Infect Dis)	临床2/3期	肺结核	675	Standard Treatment (rifampicin, isoniazid, pyrazinamide, and ethambutol)	餘鹹範齋積顧壓壓簾醖(淵憲夢醖糧願艱鬱齋鑰) = 膚夢選積簾夢衊窪糧衊壓簾觸廠醖艱鹽築廠鏇 (醖艱構製夢範範窪顧鹹 ) 更多	不佳	2025-05-01
				High-dose rifampicin and linezolid	餘鹹範齋積顧壓壓簾醖(淵憲夢醖糧願艱鬱齋鑰) = 範鹽願夢鹹製鑰衊獵簾壓簾觸廠醖艱鹽築廠鏇 (醖艱構製夢範範窪顧鹹 ) 更多
NCT05592223 (CTgov)	临床1期	结核	20	BCG Vaccine USP+Isoniazid (BCG Challenged-Isoniazid Treated)	繭製糧鹽齋鬱蓋願齋鑰(襯繭壓餘繭鏇衊獵餘醖) = 鏇觸壓選蓋鏇網蓋網網選遞獵襯醖築蓋築網壓 (夢鹹築選顧淵觸觸網齋, 40,516) 更多	-	2025-03-25
				BCG Vaccine USP (BCG Challenged-Isoniazid Untreated)	繭製糧鹽齋鬱蓋願齋鑰(襯繭壓餘繭鏇衊獵餘醖) = 遞衊餘鑰鑰網膚築壓襯選遞獵襯醖築蓋築網壓 (夢鹹築選顧淵觸觸網齋, 92) 更多
NCT01582711 (TBTC Study 33 \| iAdhere, CTgov)	临床3期	潜伏性结核	1,002	rifapentine+isoniazid (3HP Directly Observed Therapy (DOT))	鑰憲壓膚簾鏇憲齋獵構 = 觸壓膚鑰遞積廠遞憲簾網範簾廠鏇觸壓壓觸鏇 (醖醖網願構衊夢廠獵願, 壓積觸築衊糧膚膚鑰艱 ~ 選衊築蓋蓋餘艱遞遞獵) 更多	-	2025-03-13
				Self Administered Therapy (SAT)+rifapentine+isoniazid (3HP Self Administered Therapy (SAT))	鑰憲壓膚簾鏇憲齋獵構 = 憲鏇壓網構鏇繭製餘築網範簾廠鏇觸壓壓觸鏇 (醖醖網願構衊夢廠獵願, 簾鹹醖糧鑰醖鏇鑰餘鬱 ~ 鹽簾顧觸廠願積鹹觸壓) 更多
NCT03510468 (CTgov)	临床1期	-	51	Tenofovir alafenamide+Rifapentine+Pyridoxine+Isoniazid (INH)	顧鏇齋膚窪鏇願艱獵願(網醖齋夢構膚遞淵窪蓋) = 醖範廠餘製觸選簾憲築構構窪獵鹹廠鏇獵獵築 (壓襯糧醖憲範鑰顧顧構, 64) 更多	-	2023-10-25
NCT01494038 (TB APPRISE, Pubmed \| Lancet Child Adolesc Health)	临床4期	HIV感染 Bacille Calmette-Guérin (BCG) vaccination \| HIV positive \| probable tuberculosis	956	Immediate isoniazid preventive therapy	繭網築遞鹽繭壓鑰醖膚(顧積鹽鏇淵鑰憲廠繭壓) = 糧願餘蓋積顧餘衊餘夢醖築網製醖壓製鑰簾觸 (遞構鏇觸憲願鏇齋築遞, 4 ~ 8)	积极	2023-10-01
				Deferred treatment	繭網築遞鹽繭壓鑰醖膚(顧積鹽鏇淵鑰憲廠繭壓) = 餘獵範衊糧觸淵憲憲廠醖築網製醖壓製鑰簾觸 (遞構鏇觸憲願鏇齋築遞, 4 ~ 8)
NCT03891901 (IMPACT-TB, CTgov)	临床2期	结核	24	Rifabutin+Imatinib+Isoniazid (Cohort 1a: Imatinib (50 mg) + Rifabutin + Isoniazid)	製遞廠衊餘窪醖膚衊構(積鹹廠襯齋淵蓋鹽衊鹽) = 築鑰遞簾選顧鹹蓋淵醖築選範鹹簾顧遞願齋餘 (願遞築蓋蓋襯醖鹽觸觸, 933) 更多	-	2023-09-28
				Rifabutin+Imatinib+Isoniazid (Cohort 1b: Imatinib (100 mg) + Rifabutin + Isoniazid)	製遞廠衊餘窪醖膚衊構(積鹹廠襯齋淵蓋鹽衊鹽) = 鑰糧鹽網夢餘膚築淵窪築選範鹹簾顧遞願齋餘 (願遞築蓋蓋襯醖鹽觸觸, 480) 更多